Journal of Oncology Pharmacy Practice最新文献_第8页

Effectiveness and safety of trastuzumab-anns compared to reference trastuzumab among patients with HER2-positive breast cancer: A non-inferiority study. 在her2阳性乳腺癌患者中，曲妥珠单抗- annans与参考曲妥珠单抗的有效性和安全性：一项非劣效性研究

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-27 DOI: 10.1177/10781552261432500

Patrick Shin, Fang Niu, Dara D Nguyen, Stephanie L Ho, Nina Shah, Lara Durna, Rita L Hui

{"title":"Effectiveness and safety of trastuzumab-anns compared to reference trastuzumab among patients with HER2-positive breast cancer: A non-inferiority study.","authors":"Patrick Shin, Fang Niu, Dara D Nguyen, Stephanie L Ho, Nina Shah, Lara Durna, Rita L Hui","doi":"10.1177/10781552261432500","DOIUrl":"https://doi.org/10.1177/10781552261432500","url":null,"abstract":"IntroductionThis study evaluated the real-world effectiveness and safety of biosimilar trastuzumab-anns to the reference trastuzumab in a United States (U.S.) population.MethodsThis observational, multicenter, non-inferiority cohort study used electronic medical records from an integrated U.S. healthcare system. Eligible patients were HER2 + breast cancer patients treated with trastuzumab-anns (August 2019-December 2020) or trastuzumab (March 2017-July 2018). Patients were stratified by treatment setting (curative or palliative) and followed for up to 12 months, death, or end of membership, whichever occurred first. The effectiveness outcome was treatment failure, a composite of all-cause mortality or treatment change. The NI margin was set with an upper limit of 5% and multivariate Cox proportional hazards models were used. The safety was assessed by the incidence of cardiomyopathy and neutropenia. Sensitivity analysis was conducted using stabilized inverse probability of treatment weighting.ResultsOf the 4,111 patients eligible, 1,784 met the inclusion criteria with 893 patients in the trastuzumab-anns group and 891 in the reference trastuzumab group. For the composite of treatment failure, trastuzumab-anns was non-inferior to trastuzumab at 7.7% and 5.6%, respectively (90% CI: 0.0% to 4.0%; p < 0.01). A two-way analysis with Cox proportional hazard models showed no significant difference in the risk of treatment failure (adjusted hazards ratio 0.88, 95% CI: 0.6 to 1.3; p = 0.52). Rates of cardiomyopathy and neutropenia were comparable between groups.ConclusionIn this real-world U.S. population, trastuzumab-anns was non-inferior to reference trastuzumab in the treatment of HER2 + breast cancer.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261432500"},"PeriodicalIF":0.9,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neutropenia and G-CSF use in patients receiving FOLFOX during the COVID-19 pandemic. COVID-19大流行期间接受FOLFOX治疗的患者中性粒细胞减少和G-CSF的使用

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-26 DOI: 10.1177/10781552261434482

Berkan Karabuğa, Hatice Gülgün Fırat, Fatih Tay, Ekin Konca Karabuğa, Ergin Aydemir, Osman Bilge Kaya, Mehmet Emin Yılmaz, Sedef Tatar Bolat, Ayşe Ocak Duran, Mustafa Büyükkör

{"title":"Neutropenia and G-CSF use in patients receiving FOLFOX during the COVID-19 pandemic.","authors":"Berkan Karabuğa, Hatice Gülgün Fırat, Fatih Tay, Ekin Konca Karabuğa, Ergin Aydemir, Osman Bilge Kaya, Mehmet Emin Yılmaz, Sedef Tatar Bolat, Ayşe Ocak Duran, Mustafa Büyükkör","doi":"10.1177/10781552261434482","DOIUrl":"https://doi.org/10.1177/10781552261434482","url":null,"abstract":"BackgroundDuring the COVID-19 pandemic, guidance broadened indications for primary G-CSF prophylaxis to reduce chemotherapy-related neutropenia while minimizing clinic visits. Evidence on the optimal duration of daily G-CSF in biweekly FOLFOX remains limited, particularly in gastrointestinal malignancies.MethodsWe conducted a retrospective study of COVID-negative adults with gastrointestinal cancers receiving FOLFOX during the pandemic. Patients were categorized by G-CSF strategy: no prophylaxis, 3-day filgrastim, or 5-day filgrastim. Primary outcomes were overall neutropenia and grade 3-4 neutropenia. Secondary outcomes included treatment modifications and adverse events. Multivariable logistic regression assessed independent associations.ResultsNeutropenia was higher without G-CSF versus 3-day and 5-day (64.4% vs 37.1% vs 39.6; p < 0.001); grade 3-4 neutropenia likewise (30.1% vs 7.9% vs 11.9; p < 0.001). 3-day vs 5-day showed no significant difference (neutropenia p = 0.67; grade 3-4 p = 0.29). G-CSF use independently lowered neutropenia risk; female sex independently increased risk.ConclusionIn patients receiving biweekly FOLFOX for gastrointestinal cancers, primary G-CSF prophylaxis was associated with lower rates of neutropenia. No statistically significant difference was observed between the 3-day and 5-day daily G-CSF schedules in this cohort. However, given the retrospective design and the absence of a predefined non-inferiority framework, these findings do not establish equivalence and should be interpreted with caution. Prospective multicenter studies specifically designed to compare 3- and 5-day regimens are warranted.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261434482"},"PeriodicalIF":0.9,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147512779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safe handling of antineoplastic drugs: Nurses' knowledge, attitudes, and practices in a Malaysian Tertiary hospital. 抗肿瘤药物的安全处理：马来西亚三级医院护士的知识、态度和实践。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-26 DOI: 10.1177/10781552261422459

Muhammad Idham Jasmiad, Nur Izzati Mansor, Amira Raudhah Abdullah, Noor Wahidah Mohd Nasri, Aslina Mohamed Yasin

{"title":"Safe handling of antineoplastic drugs: Nurses' knowledge, attitudes, and practices in a Malaysian Tertiary hospital.","authors":"Muhammad Idham Jasmiad, Nur Izzati Mansor, Amira Raudhah Abdullah, Noor Wahidah Mohd Nasri, Aslina Mohamed Yasin","doi":"10.1177/10781552261422459","DOIUrl":"https://doi.org/10.1177/10781552261422459","url":null,"abstract":"IntroductionAntineoplastic agents (ANPDs) are mainly used in the treatment of cancer, with known health risks to nurses involved in the handling of these agents. Despite growing awareness, studies continue to reveal incomplete adherence to the handling guidelines and practice. Hence, assessment of nurses' knowledge, attitude, and practice (KAP) is vital. The study aims to identify the level of KAP among nurses at a Tertiary hospital in Klang Valley, Malaysia, regarding safe handling of ANPDs.MethodsA cross-sectional survey design was conducted on (n = 120) nurses at Klang Valley, Malaysia, using a random sampling method. The data collection tools were a self-administered questionnaire that consisted of 33 questions from a published study with a Cronbach alpha of 0.7. KAP scores were analysed descriptively, and sociodemographic correlations were analysed using multiple linear regression analysis.ResultsThe findings indicated that 43.3% of nurses demonstrated a good level of knowledge (mean score: 54.78 ± 4.87). Additionally, 54.2% demonstrated a good attitude (33.69 ± 2.90), and 55% exhibited good practice scores (53.09 ± 5.20). A statistically significant positive correlation (P < 0.001) was observed between knowledge and attitudes, as well as between knowledge and practices. However, multivariable regression analysis identified attitude as the significant independent predictor of safe handling practices.ConclusionThe study highlights the need for the establishment of a formal protocol and training for nurses involved in the handling of ANPDs.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261422459"},"PeriodicalIF":0.9,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147512848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners. CDK4/6抑制剂在侵袭性小叶癌中的疗效、耐药模式和内分泌伙伴

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-24 DOI: 10.1177/10781552261434861

Saim Mahmood Khan, Aroobah Jawwad, Maheen Kashif, Bisma Abbas, Saroosh Kabir, Aiman Badar, Hafsa Sheikh, Anab Azam, Surraiya Riaz Mahmood Khan

{"title":"CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners.","authors":"Saim Mahmood Khan, Aroobah Jawwad, Maheen Kashif, Bisma Abbas, Saroosh Kabir, Aiman Badar, Hafsa Sheikh, Anab Azam, Surraiya Riaz Mahmood Khan","doi":"10.1177/10781552261434861","DOIUrl":"https://doi.org/10.1177/10781552261434861","url":null,"abstract":"BackgroundBreast cancer (BC) remains the most common malignancy in women, with 10-15% being invasive lobular carcinoma (ILC). ILC is typically estrogen receptor (ER) positive, slow-growing, and characterized by multicentricity, multifocality, bilateral involvement, and a distinct metastatic pattern.ObjectivesThis review summarizes recent evidence on CDK4/6 inhibitors combined with endocrine therapy in hormone receptor-positive ILC and explores optimal first-line regimens to overcome resistance.MethodologyA literature search from 2019 to 2025 was conducted in PubMed, Web of Science, and Google Scholar for randomized trials, observational studies, meta-analyses, and translational research on endocrine therapy, CDK4/6 inhibitors, resistance mechanisms, and ILC-specific molecular features. Studies assessing treatment efficacy and resistance pathways were prioritized.ResultsCDK4/6 inhibitors plus endocrine therapy significantly improve progression-free and invasive disease-free survival in HR+/HER2- BC, including ILC. In a pooled FDA analysis of seven phase III trials (n > 4000), combination therapy had an HR of 0.59. In the ILC subgroup (n = 264), median PFS was 16.1 vs 9.2 months (HR 0.58), comparable to the overall population. First-line aromatase inhibitors with CDK4/6 inhibitors enhance overall survival, while fulvestrant combinations benefit endocrine-resistant cases. Early combination therapy is more effective than delayed treatment. Real-world data support these findings.ConclusionCDK4/6 inhibitors with endocrine therapy markedly improve survival in HR+/HER2- BC, yet ILC-focused trials and standardized reporting are limited. Future research should prioritize routine, centralized reporting of ILC subtypes to guide evidence-based, subtype-specific treatment strategies.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261434861"},"PeriodicalIF":0.9,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of chemotherapy dosing and regimen optimization in geriatric oncology patients diagnosed with solid organ malignancies. 诊断为实体器官恶性肿瘤的老年肿瘤患者化疗剂量和方案优化的评估。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-23 DOI: 10.1177/10781552261433970

Prajwal R Shankar, Harshitha Bv, Sangeetha S, Shobha Rani Rh, Priyank Tripathi, Sateesh Ct, Govind Babu K, Shekar Patil, Nazath Unissa, Spoorti G

{"title":"Assessment of chemotherapy dosing and regimen optimization in geriatric oncology patients diagnosed with solid organ malignancies.","authors":"Prajwal R Shankar, Harshitha Bv, Sangeetha S, Shobha Rani Rh, Priyank Tripathi, Sateesh Ct, Govind Babu K, Shekar Patil, Nazath Unissa, Spoorti G","doi":"10.1177/10781552261433970","DOIUrl":"https://doi.org/10.1177/10781552261433970","url":null,"abstract":"IntroductionThe rising geriatric population has led to an increase in cancer diagnoses, with treatment decisions complicated by variable functional status and co-morbidities. This study compared chemotherapy dosing strategies, evaluated efficacy and safety, explored correlations with CRASH, CARG, G8, and CGA tools, and examined cancer incidence in older patients.MethodsA hospital-based retro-prospective study was conducted at tertiary care cancer hospital over six months, with prior ethical approval. Patients aged ≥65 years with solid organ malignancies receiving chemotherapy were assessed using the Cancer and Aging Research Group (CARG), Chemotherapy Risk Assessment Scale for High Age Patients (CRASH), and Geriatric-8 (G8) tools. Those failing G8 underwent Comprehensive Geriatric Assessment (CGA). Statistical analysis was performed using the Kruskal-Wallis test.ResultsA total of 154 patients were enrolled (88 males, 57.1%; 66 females, 42.9%). Of these, 71 (46.1%) received standard doses, while 83 (53.9%) received reduced doses during the first cycle. Among 109 patients failing G8, CGA was conducted. Adverse effects-including weakness, nausea, and ulcers occurred in 78 patients (71.6%). Depression correlated significantly with CARG (p=0.02). CRASH and CARG showed no direct correlation (p=0.433); however, ADRs were significantly associated with CRASH (p=0.01), while dosage adjustments correlated with CARG (p=0.04).ConclusionCancer care in geriatric patients requires individualised dosing guided by structured screening and geriatric assessment tools. Integrating CARG, CRASH, G8, and CGA into treatment planning enhances safety and efficacy by balancing therapeutic benefits with toxicity risks.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261433970"},"PeriodicalIF":0.9,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of treatment duration on quality of life, economic burden, and work productivity among chronic myeloid leukemia survivors. 治疗时间对慢性髓性白血病幸存者生活质量、经济负担和工作效率的影响。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-23 DOI: 10.1177/10781552261430662

Lingling Li, Sasa Li, Youwei Yang, Xiaofang Hou, Linlin Wu

{"title":"The impact of treatment duration on quality of life, economic burden, and work productivity among chronic myeloid leukemia survivors.","authors":"Lingling Li, Sasa Li, Youwei Yang, Xiaofang Hou, Linlin Wu","doi":"10.1177/10781552261430662","DOIUrl":"https://doi.org/10.1177/10781552261430662","url":null,"abstract":"ObjectiveTo explore the impact of treatment duration on quality of life (QoL), economic burden, and work productivity among chronic myeloid leukemia (CML) survivors.MethodsA single-center cross-sectional design was adopted, and 72 CML survivors who received treatment for ≥3 months were enrolled. Correlation analysis and multivariate linear regression were used to analyze the association between treatment duration and the outcomes.ResultsTreatment duration was an independent negative predictor of overall QoL (β = -0.013, p < 0.001) and an independent positive predictor of perceived economic burden (β = 0.023, p < 0.001) and overall work productivity loss rate (β = 0.302, p < 0.001). Stratified analysis showed that treatment duration was significantly positively correlated with economic burden in low-income patients and those receiving combined therapy or post-transplant maintenance therapy (both p = 0.008), with total treatment costs mediating 60.9% of this association. Additionally, TKI monotherapy, higher household income, stronger social support, and better physical function were protective factors for QoL, while anxiety and depression were associated with more adverse outcomes.ConclusionProlonged treatment duration is associated with reduced QoL, increased economic burden, and impaired work productivity in CML survivors, with these associations modulated by socioeconomic status, treatment modality, and mental health.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261430662"},"PeriodicalIF":0.9,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of chemotherapy versus targeted therapy in breast cancer: A retrospective analysis in tertiary care hospital. 乳腺癌化疗与靶向治疗的成本-效果：三级医院回顾性分析

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-23 DOI: 10.1177/10781552261427334

Naresh Kunta, Sriharsha Varakala, Vaishnavi Devi, Yogyatha Nemmani, Jagadeeshwar Ksheerasagar, Tulja Rani Gampa, Swapna Jilla

{"title":"Cost-effectiveness of chemotherapy versus targeted therapy in breast cancer: A retrospective analysis in tertiary care hospital.","authors":"Naresh Kunta, Sriharsha Varakala, Vaishnavi Devi, Yogyatha Nemmani, Jagadeeshwar Ksheerasagar, Tulja Rani Gampa, Swapna Jilla","doi":"10.1177/10781552261427334","DOIUrl":"https://doi.org/10.1177/10781552261427334","url":null,"abstract":"BackgroundBreast cancer represents a significant economic burden globally, with treatment costs varying substantially between conventional chemotherapy and newer targeted therapies. Economic evaluation is essential for healthcare decision-making, particularly in resource-limited settings.ObjectiveTo evaluate the cost-effectiveness of targeted therapy versus chemotherapy in breast cancer treatment from a healthcare system perspective in an Indian tertiary care hospital setting.MethodsA retrospective cost-effectiveness analysis was conducted comparing patients receiving chemotherapy versus targeted therapy for breast cancer. Direct medical costs were calculated including drug costs, hospitalization, and diagnostic services. Health outcomes were measured using quality-adjusted life years (QALYs) derived from patient-reported EQ-5D visual analogue scale (VAS) based utility values accrued during treatment and post-treatment progression-free survival. The incremental cost-effectiveness ratio (ICER) was calculated and compared against India's willingness-to-pay threshold based on per capita GDP.ResultsThe analysis included two treatment groups: chemotherapy (mean cost: ₹52,173) and targeted therapy (mean cost: ₹1,044,113). QALYs achieved were significantly higher in the targeted therapy group (2.398 vs 1.083, p < 0.001). The ICER for targeted therapy was ₹754,264 per QALY gained, which falls below willingness-to-pay threshold of 2-3 times per capita GDP (₹806,428-₹1,209,642).ConclusionsDespite substantially higher treatment costs, targeted therapy demonstrates cost-effectiveness compared to chemotherapy when considering health outcomes. The ICER remains within acceptable thresholds for India, supporting targeted therapy as a cost-effective treatment option for appropriate breast cancer patients.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261427334"},"PeriodicalIF":0.9,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147504028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) database. 使用FDA不良事件报告系统（FAERS）数据库对FGFR抑制剂福替替尼进行药物警戒分析。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-21 DOI: 10.1177/10781552261433918

Connor Frey

{"title":"Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) database.","authors":"Connor Frey","doi":"10.1177/10781552261433918","DOIUrl":"https://doi.org/10.1177/10781552261433918","url":null,"abstract":"BackgroundFutibatinib, a novel FGFR inhibitor, is a promising therapy for cancers with FGFR alterations. However, its safety profile remains under investigation. This study evaluates futibatinib-associated adverse events using the FDA Adverse Event Reporting System (FAERS).MethodsA retrospective pharmacovigilance analysis was conducted using FAERS data from January 1, 2013, to March 9, 2025. Disproportionality analysis was performed via OpenVigil 2.1, with signals defined by a reporting odds ratio (ROR) > 2.00 and a 95% confidence interval lower bound >1.00. Events with at least two reports were included after deduplication and standardization.ResultsStrong safety signals were identified. Hyperphosphatasemia showed the highest association (ROR 1612.73; 6 events), followed by elevated blood phosphorus (ROR 603.85; 3 events). Dermatologic toxicities, including onycholysis (ROR 520.15) and onychoclasis (ROR 126.20), were also notable.ConclusionThese findings highlight the range of adverse events associated with this agent. These events may reflect direct drug effects and individual variability. Further studies are needed to clarify mechanisms and inform clinical management.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261433918"},"PeriodicalIF":0.9,"publicationDate":"2026-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147494247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of healthcare providers' training (ISOPP-OPAB) on biosimilars use for cancer care at a university hospital in Nigeria. 尼日利亚一所大学医院医疗保健提供者培训（ISOPP-OPAB）对生物仿制药用于癌症治疗的影响。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-21 DOI: 10.1177/10781552261428431

Modupe Lydia Olarewaju, Raheem Bolanle Rahamon, Oluwabusayo Abolarin, Temitope Kemi Asishana, Rapheal Ibregbe, Alexandre Chan

{"title":"Impact of healthcare providers' training (ISOPP-OPAB) on biosimilars use for cancer care at a university hospital in Nigeria.","authors":"Modupe Lydia Olarewaju, Raheem Bolanle Rahamon, Oluwabusayo Abolarin, Temitope Kemi Asishana, Rapheal Ibregbe, Alexandre Chan","doi":"10.1177/10781552261428431","DOIUrl":"https://doi.org/10.1177/10781552261428431","url":null,"abstract":"This study assessed the impact of a targeted training program offered by the International Society of Oncology Pharmacy Practitioners in enhancing biosimilar knowledge among healthcare professionals at the University of Ilorin Teaching Hospital, Nigeria, addressing the critical need for cost-effective cancer care. An interventional, pre- and post-test design was employed, involving 24 healthcare professionals comprising of 16 physicians, 3 pharmacists, and 5 nurses. Participants underwent a one-day training session focused on biologics, biosimilars, and their clinical applications in cancer care, delivered by trained oncology pharmacists. Comparison of pre- and post-training knowledge was assessed using a standardized questionnaire. Statistical analysis, including descriptive statistics and paired t-tests, was conducted to evaluate the impact of the intervention.Results demonstrated a significant improvement in biosimilar knowledge following the training. The mean (±SD) post-test score (7.3 ± 3.0) was significantly higher than the mean pre-test score (4.6 ± 2.3), with a 2.7-point increase (p < 0.001). Despite participants' professional experience, baseline knowledge was notably low compared to the post-test. The training program effectively bridged this knowledge gap, indicating its potential to facilitate biosimilar adoption. This study concludes that targeted training significantly enhances healthcare professionals' understanding of biosimilars. Continued education and training are crucial to optimizing biosimilar implementation and improving access to affordable cancer care in resource-limited settings.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261428431"},"PeriodicalIF":0.9,"publicationDate":"2026-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147494212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduced initial Pazopanib dosing strategy for recurrent, advanced, or metastatic sarcoma: A single center experience. 减少复发性、晚期或转移性肉瘤的初始帕唑帕尼剂量策略：单中心经验。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-21 DOI: 10.1177/10781552251414698

Chaeyeong Jang, Kevin Chen, Samantha A Armstrong, Stephanie Schneck, Michael Groswald, Allison Crone, Ruobing He, Sarah Spargo

{"title":"Reduced initial Pazopanib dosing strategy for recurrent, advanced, or metastatic sarcoma: A single center experience.","authors":"Chaeyeong Jang, Kevin Chen, Samantha A Armstrong, Stephanie Schneck, Michael Groswald, Allison Crone, Ruobing He, Sarah Spargo","doi":"10.1177/10781552251414698","DOIUrl":"https://doi.org/10.1177/10781552251414698","url":null,"abstract":"IntroductionPazopanib is a treatment option for patients who have advanced or metastatic soft tissue sarcoma. Although the FDA label recommends pazopanib 800 mg q24h as the initial dose, the starting dose in clinical practice can range from 200 mg to 800 mg q24h due to poor tolerability. This study describes a single institution's experience and outcomes of using pazopanib for patients with sarcoma.MethodsA retrospective chart review was conducted for adult patients with recurrent, advanced, or metastatic sarcoma who were prescribed pazopanib between 2014 and 2022 at Indiana University Simon Comprehensive Cancer Center.ResultsOf 148, 66 patients met the inclusion criteria. Median starting dose and frequency of pazopanib was 300 mg q24h (range, 200 mg q48h-800 mg q24h) with 200 mg q24h (48%) being the most common. Median time on pazopanib was 5.5 months (range, 0.62-100 months). Median progression free survival was 4.4 months (95% CI, 3.3-9.4), and median overall survival was 29 months (95% CI, 21.8-NE). The most common toxicities were fatigue (51%), hypertension (37%), nausea/vomiting (34%), and diarrhea (33%). Treatment interruptions occurred in 45% of patients, and dose reductions in 30% of patients.ConclusionsLower starting dose of pazopanib did appear to reduce the risk of various side effects compared to the PALETTE trial, suggesting a potential benefit of this dosing strategy given similar clinical efficacy. Further comparative studies examining lower initial dose vs full-dose initiation are needed to determine differences in patient tolerability and clinical outcomes.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251414698"},"PeriodicalIF":0.9,"publicationDate":"2026-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147494239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0